253 related articles for article (PubMed ID: 31523950)
21. Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.
Mamchak AA; Manenkova Y; Leconet W; Zheng Y; Chan JR; Stokes CL; Shoda LK; von Herrath M; Bresson D
Diabetes; 2012 Jun; 61(6):1490-9. PubMed ID: 22362174
[TBL] [Abstract][Full Text] [Related]
22. Teplizumab therapy for type 1 diabetes.
Masharani UB; Becker J
Expert Opin Biol Ther; 2010 Mar; 10(3):459-65. PubMed ID: 20095914
[TBL] [Abstract][Full Text] [Related]
23. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
[TBL] [Abstract][Full Text] [Related]
24. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance.
von Herrath MG; Coon B; Wolfe T; Chatenoud L
J Immunol; 2002 Jan; 168(2):933-41. PubMed ID: 11777992
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Herold KC; Hagopian W; Auger JA; Poumian-Ruiz E; Taylor L; Donaldson D; Gitelman SE; Harlan DM; Xu D; Zivin RA; Bluestone JA
N Engl J Med; 2002 May; 346(22):1692-8. PubMed ID: 12037148
[TBL] [Abstract][Full Text] [Related]
26. Teplizumab: First Approval.
Keam SJ
Drugs; 2023 Apr; 83(5):439-445. PubMed ID: 36877454
[TBL] [Abstract][Full Text] [Related]
27. Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.
Miller SA; St Onge E
Expert Opin Biol Ther; 2011 Nov; 11(11):1525-32. PubMed ID: 21913874
[TBL] [Abstract][Full Text] [Related]
28. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
Vudattu NK; Herold KC
Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH.
Ilan Y; Shailubhai K; Sanyal A
Clin Exp Immunol; 2018 Sep; 193(3):275-283. PubMed ID: 29920654
[TBL] [Abstract][Full Text] [Related]
30. A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.
Gill RG; Pagni PP; Kupfer T; Wasserfall CH; Deng S; Posgai A; Manenkova Y; Bel Hani A; Straub L; Bernstein P; Atkinson MA; Herold KC; von Herrath M; Staeva T; Ehlers MR; Nepom GT
Diabetes; 2016 May; 65(5):1310-6. PubMed ID: 26718498
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes.
Aly T; Devendra D; Eisenbarth GS
Am J Ther; 2005; 12(6):481-90. PubMed ID: 16280641
[TBL] [Abstract][Full Text] [Related]
32. Making progress: preserving beta cells in type 1 diabetes.
Gallagher MP; Goland RS; Greenbaum CJ
Ann N Y Acad Sci; 2011 Dec; 1243():119-34. PubMed ID: 22211897
[TBL] [Abstract][Full Text] [Related]
33. Type 1 diabetes intervention trials 2007: where are we and where are we going?
Haller MJ; Gottlieb PA; Schatz DA
Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):283-7. PubMed ID: 17940453
[TBL] [Abstract][Full Text] [Related]
34. Anti-CD3 drug keeps diabetes at bay.
Dolgin E
Nat Biotechnol; 2019 Oct; 37(10):1099-1101. PubMed ID: 31578500
[No Abstract] [Full Text] [Related]
35. Otelixizumab in the treatment of type 1 diabetes mellitus.
Sprangers B; Van der Schueren B; Gillard P; Mathieu C
Immunotherapy; 2011 Nov; 3(11):1303-16. PubMed ID: 22053883
[TBL] [Abstract][Full Text] [Related]
36. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
Fanaropoulou NM; Tsatsani GC; Koufakis T; Kotsa K
Expert Rev Clin Immunol; 2024 Feb; 20(2):185-196. PubMed ID: 37937833
[TBL] [Abstract][Full Text] [Related]
37. Perturbed homeostasis of peripheral T cells elicits decreased susceptibility to anti-CD3-induced apoptosis in prediabetic nonobese diabetic mice.
Yang W; Hussain S; Mi QS; Santamaria P; Delovitch TL
J Immunol; 2004 Oct; 173(7):4407-16. PubMed ID: 15383571
[TBL] [Abstract][Full Text] [Related]
38. Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.
Staeva-Vieira T; Peakman M; von Herrath M
Clin Exp Immunol; 2007 Apr; 148(1):17-31. PubMed ID: 17349010
[TBL] [Abstract][Full Text] [Related]
39. [Clinical study of the month. Attempt at preservation of B cells during the initial phase of type 1 diabetes: negative results with ultralente insulin, but promising results with an anti-CD3 monoclonal antibody].
Philips JC; Scheen AJ;
Rev Med Liege; 2002 Jun; 57(6):413-7. PubMed ID: 12180038
[TBL] [Abstract][Full Text] [Related]
40. [Prevent and cure insulin-dependent diabetes].
Bach JF
Pathol Biol (Paris); 2003 Apr; 51(3):151-5. PubMed ID: 12781796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
